Involvement of the transforming growth factor β in the pathogenesis hereditary hemorrhagic telangiectasia

Current Pharmaceutical Design

Volumn 12, Issue 10, 2006, Pages 1195-1200

  Jirillo, E ^a,b,c   Amati, L ^a   Suppressa, P ^b   Cirimele, D ^a   Guastamacchia, E ^b   Covelli, V ^c   Tafaro, E ^b   Sabba C ^b  

^a Sci Institute of Gastroenterology   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c POLICLINICO   (Italy)

Author keywords

Activin receptor like kinase 1; Angiogenesis; Endoglin; Hereditary hemorrhagic telangiectasia; Immunity; Transforming growth factor; Tumorigenesis

Indexed keywords

AUTOANTIBODY; CYTOKINE; ENDOGLIN; MYC PROTEIN; PROTEIN P15; PROTEIN P21; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ARTERIOVENOUS MALFORMATION; CARCINOGENESIS; CLINICAL FEATURE; CONGENITAL HEART BLOCK; DISEASE COURSE; ENDOTHELIUM CELL; ENTERITIS; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GASTROINTESTINAL DISEASE; GENE MUTATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNE SYSTEM; IMMUNOREGULATION; LIVER DISEASE; MUTATIONAL ANALYSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FAMILY; REGULATORY MECHANISM; RENDU OSLER WEBER DISEASE; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; VENULE; GENETICS; IMMUNOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

GASTROINTESTINAL DISEASES; HUMANS; LIVER DISEASES; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 33744996748     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776361228     Document Type: Review

References (101)

1. Ranieri G, Gasparini G. Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy. Carr Drug Targets Immune Endocr Metabol Disord 2001; 1:241-53.
2. Jacobson BS. Hereditary hemorrhagic telangiectasia: A model for blood vessel growth and enlargement. Am J Pathol 2000; 156: 737-42.
3. Braverman M, Keh A, Jacobson BS. Ultrastructure and three-dimensional organization of the telangiectases of hereditary hemorrhagic telangiectasia. J Invest Dermatol 1990; 95:422-7
4. Mc Allister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1: Nat Genet 1994; 8:345-51.
5. Johnson DW, Berg JN, Gallione CJ, McAllister KA, Warner JP, Helmbold EA, et al. A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genome Res 1995; 5:21-28.
6. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-91.
7. Goumans M-J, Lebrin F, Valdimarsdottrin G. Controlling the angiogenic switch: a balance between two distinct TGF-beta receptor signaling pathways. Trends Cardiovasc Med 2003; 13:301-7.
8. Dennler S, Goumans M-J, Ten Dike P. Transforming growth factor beta signal transduction. J Leukoc Biol 2002; 71:731-40.
9. Lutz M, Knaus P. Integration of the TGF-beta pathway into the cellular signaling network. Cell Signal 2002; 14:977-88.
10. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol, 1998; 16: 137-61.
11. Chen W, Frank ME, Jin W, Wahl SM. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 2001; 14: 715-25.
12. Moustakas A, Pardali K, Gaal A, Heldin C-H. Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol Lett 2002; 82: 85-91.
13. Franzèn P, Ten Dijke P, Ichijo H, Yamashita H, Schulz P, Heldin C-H, et al. Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell 1993; 75:681-92.
14. Lin HY, Wang XF, Ng-Eaton E, Weinberg RA, Lodish HF. Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/ threonine kinase. Cell 1992: 68: 775-85.
15. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-beta receptor. Nature 1994; 370: 341-47.
16. Lux A, Attisano L, Marchuk DA. Assignment of transforming growth factor beta1 and beta3 and a third now ligand to the type I receptor ALK-1. J Biol Chem 1999; 274: 9984-92.
17. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 2000; 97: 2626-31.
18. Goumans MJ, Mummery C. Functional analysis of the TGFbeta receptor/Smad pathway through gene ablation in mice. Int J Dev Biol 2000; 44: 253-65.
19. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-58.
20. Cerwenka A, Swain SL. TGF-beta1: immunosuppressant and viability factor for T lymphocytes. Microbes Infect 1999; 1: 1291-96.
21. Lebman DA, Edmiston JS. The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes. Microbes Infect 1999; 1: 1297-304.
22. Mc Cartney-Francis NL, Fralier-Jessen M, Wahl SM. TGF-beta: a balancing act. Int Rev Immunol 1998; 16: 553-80.
23. Cazac BB, Roes J. TGF-beta receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 2000; 13: 443-51.
24. Gorelik L, Flavell RA. Abrogation of TGF-beta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12: 171-81.
25. Ludviksson BR, Seegers D, Resnick AS, Strober W. The effect of TGF-beta1 on immune responses of naive versus memory CD4+ Th1/Th2 T cells. Eur J Immunol 2000; 30: 2101-111.
26. Roberts AB. Molecular and cell biology of TGF-beta. Miner Electrolyte Metab 1998; 24:111-19.
27. McGuirk P, Mills KH. Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol 2002; 23: 450-55.
28. Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 1996; 98: 70-77.
29. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2: 389-400.
30. Chen Y, Ebright YW, Ebright RH. Identification of the target of a transcription activator protein by protein-protein photocrosslinking. Science 1994; 265: 1237-40.
31. Seo N, Hayakawa S, Takigawa M, Tokura Y. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology 2001; 103: 449-57.
32. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001; 194: 629-44.
33. Lucas PJ, Kim SJ, Melby SJ, Gress RE. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor. J Exp Med 2000; 191: 1187-96.
34. Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med 2002; 196: 255-60.
35. Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000; 1: 199-205.
36. Amati L, Passeri ME, Resta, F, Triggiani V, Jirillo E, Sabbà C. Ablation of T-Helper 1 Cell Derived Cytokines and of Monocyte-Derived Tumor Necrosis Factor-α in Hereditary Hemorrhagic Telangiectasia: Immunological Consequences and Clinical Considerations Curr Pharm Design 2005; 11(??): ????-????.
37. Cirulli A, Loria MP, Dambra P, Di Serio F, Ventura MT, Amati L, et al. Patients with Hereditary Hemorrhagic Telangectasia (HHT) Exhibit a Deficit of Polymorphonuclear Cell and Monocyte Oxidative Burst and Phagocytosis: A Possible Correlation with Altered Adaptive Immune Responsiveness in HHT. Curr Pharm Design 2005; 11(??): ????-????.
38. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693-99.
39. Christ M, Mc Cartney-Francis NL, Kulkarni AB, Ward JM, Mizel DE, Mackall CC, et al. Immune dysregulation in TGF-beta 1-deficient mice. J Immunol 1994; 153: 1936-46.
40. Van Ginkel FW, Wahl SM, Kearney JF, Kweon MN, Fujihashi K, Burrows PD, et al. Partial IgA-deficiency with increased Th2-type cytokines in TGF-beta 1 knockout mice. J Immunol 1999; 163: 1951-57.
41. Ishisaki A, Yamato K, Hashimoto S, Tamaki K, Nonaka K, Ten Dijke P, et al. Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in B cells. J Biol Chem 1999; 274: 13637-42.
42. Arsura M, Wu M, Sonenshein GE. TGF beta 1 inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: transcriptional activation of I kappa B alpha. Immunity 1996, 5: 31-40.
43. Yanagisawa K, Osada H, Masuda A, Kondo M, Saito T, Yatabe Y, et al. Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-beta in human normal lung epithelial cells. Oncogene 1998; 17: 1743-47.
44. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Veno N, et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995; 270: 2008-11.
45. Perlman R, Schiemann WP, Brooks MW, Lodish, HF, Weinberg RA. TGF-beta-induced apoptosis is mediated by the adapter protein Daxx the facilitates JNK activation. Nat Cell Biol 2001; 3: 708-14.
46. de Caestecker MP, Pick E, Roberts AB. Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 2000; 92: 1388-402.
47. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
48. Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi AL, et al. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci USA 2001; 98: 4510-15.
49. Riggins GJ, Thiagalingam S, Rozenblum E, Weinstein CL, Kern SE, Hamilton SR, et al. Mad-related genes in the human. Nat Gen 1996; 13: 347-49.
50. Decoteau JF, Knaus PI, Yankelev H, Reis MD, Lowsky R, Lodish HF, et al. Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1997; 94: 5877-81.
51. Kadin ME, Cavaille-Coll MW, Gertz R, Massaguè J, Cheifetz S, George D. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci Usa 1994, 91: 6002-6.
52. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-53.
53. Imay Y, Kurokawa M, Izutsu K, Hangahishi A, Maki K, Ogawa S. et al. Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis. Oncogene 2001; 20: 88-96.
54. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996; 86: 543-52.
55. Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, et al. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 1998; 394: 92-96.
56. Izutsu K, Kurokawa M, Imai Y, Maki K, Hirai H. The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood 2001, 97: 2815-22.
57. Akhurst RJ, Balmain A. Genetic events and the role of TGF beta in epithelial tumour progression. J Pathol 1999; 187: 82-90.
58. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev 1996; 7: 93-102.
59. Alexandrow MG, Moses HL. Kips off to Myc: implications for TGF beta signaling. J Cell Biochem 1997; 66: 427-32.
60. Oft M, Heider KH, Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 1998; 8: 1243-52.
61. Lehmann K, Janda E, Pierreux CE, Rytomaa M, Schulze A, McMahon M, et al. Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev 2000; 14: 2610-22.
62. Hsiao Ya-W, Liao K-W, Hung S-W, Chu R-M. Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-denved TGF-beta 1 and restores the lymphokine-activated killing activity. J Immunol 2004; 172: 1508-14.
63. Nagata Y, Tanaka N, Orita K. Endotoxin-induced liver injury after extended hepatectomy and the role of Kupffer cells in the rat. Jpn J Surg 1994; 24: 441-8.
64. Yachida S, Kokudo Y, Wakabayashi H, Maeta T, Kaneda K, Maeta H. Morphological and functional alterations to sinusoidal endothelial cells in the early phase of endotoxin-induced liver failure after partial hepatectomy in rats. Virchows Arch 1998; 433: 173-81.
65. Bissel DM, Roult D, George J. Transforming growth factor beta and the liver. Hepatol 2001; 34: 859-67.
66. Casini A, Pinzani M, Milani S, Grappone C, Galli G, Jezequel AM, et al. Regulation of extracellular matrix synthesis by transforming growth factor beta 1 in human fat-storing cells. Gastroenterology 1993; 105: 245-53.
67. Enami Y, Kato H, Murakami M, Fujioka T, Aoki T, Niiya T, et al. Anti-transforming growth factor-beta1 antibody transiently enhances DNA synthesis during liver regeneration after partial hepatectomy in rats. J Hep Bil Pancr Surg 2001; 8: 250-8
68. Islam M, Burke JF, McGowan TA, Zhu Y, Dunn SR, McCue P, et al. Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. Kidney Int 2001; 59: 498-506.
69. Burt AD. C. L. Oakley Lecture (1993). Cellular and molecular aspects of hepatic fibrosis. J Pathol 1993; 170: 105-14.
70. Michalopoulos GK, Defrances MC. Liver regeneration. Science 1997; 276: 60-6.
71. Freathy C, Brown DG, Roberts RA, Cain K. Transforming growth factor-beta(1) induces apoptosis in rat FaO hepatoma cells via cytochrome c release and oligomerization of Apaf-1 to form a approximately 700-kd apoptosome caspase-processing complex. Hepatology 2000; 32: 750-60.
72. Martin-Sanz P, Diaz-Guerra MJM, Casado M, Bosca L. Bacterial lipopolysaccharide antagonizes transforming growth factor beta 1-induced apoptosis in primary cultures of hepatocytes. Hepatology 1996; 23: 1200-07.
73. Alcolado R, Arthor MJP, Iredale JP. Pathogenesis of liver fibrosis. Clin Science 1997; 92: 103-12.
74. Amati L, Caradonna L, Magrone T, Mastronardi ML, Cuppone R, Cozzolongo R, et al. Modifications of the immune responsiveness in patients with hepatitis C virus infection following treatment with IFN-alpha/ ribavirin. Curr Pharm Design 2002; 8: 981-93.
75. Caradonna L, Mastronardi ML, Magrone T, Cozzolongo R, Cuppone R, Manghisi OG, et al. Biological and clinical significance of endotoxemia in the course of hepatitis C virus infection. Curr Pharm Design 2002; 8: 995-1005.
76. Russo F, Messa C, Amati L, Caradonna L, Leoci C, Di Matteo G, et al. The influence of Helicobacter pylori eradication on the gastric mucosal content of epidermal growth factor, transforming growth factor-alpha, and their common receptor. Scand J Gastroenterol 1998; 33: 271-75.
77. Lembo A, Caradonna L, Magrone T, Mastronardi ML, Caccavo D, Jirillo, et al. Helicobacter pylori infection, immune response and vaccination. Curr Drug Targets-Immun Endocrin Metabol Disord 2001: 1: 199-208.
78. Di Leo A, Messa C, Russo F, Linsalata M, Amati L, Caradonna L, et al. Helicobacter pylori infection and host cell responses. Immunopharmacol Immunotoxicol 1999; 21: 803-46.
79. Amati L, Caradonna L, Jirillo E, Caccavo D. Immunological disorders in inflammatory bowel disease and immunotherapeutic implications. Ital J Gastroenterol Hepatol 1999; 31: 313-25.
80. Caradonna L, Amati L, Magrone T, Pellegrino NM, Jirillo E, Caccavo D. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J Endotoxin Res 2000; 6: 205-14.
81. Jirillo E, Caradonna L, Greco B, Satalino R, Pugliese V, Sisto G, et. al. Circulating bacterial lipopolysaccharides (LPS) in patients with Inflammatory Bowel Disease. Microecol Therapy 1995; 25: 37-41.
82. Caradonna L, Amati L, Lella P, Jirillo E, Caccavo D. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease. Am J Gastroenterol 2000; 95: 1495-502.
83. Amati L, Caradonna L, Leandro G, Magrone T, Minenna M, Faleo G, et al. Immune abnormalities and endotoxemia in patients with ulcerative colitis and in their first degree relatives: attempts at neutralizing endotoxin-mediated effects. Curr Pharm Design 2003; 9: 1937-45.
84. Amati L, Passeri ME, Mastronardi ML, Jirillo E. Anti Tumor Necrosis Factor-α Monoclonal Antibody (Infliximab) therapy in patients with Inflammatory Bowel Disease (IBD): Applications and side effects. Drug Design Rev-On Line 2004; 2: 111-17.
85. Kuhn R, Lohler J, Rennick D, Rajewsky, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-74.
86. Groux H, Powrie F. Regulatory T cells and inflammatory bowel disease. Immunol Today 1999; 20: 442-45.
87. Neurath MF, Fuss I, Kelsall BL, Presky DH, Waegell L, Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med 1996; 183: 2605-16.
88. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994; 106: 533-39.
89. Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H, et al. TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both human and mice. J Immunol 2004; 172: 834-42.
90. Guttmacher AE, Marchuk DA, White RL. Hereditary hemorrhagic telangiectasia N Engl J Med 1995; 333: 918-24.
91. Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 1999; 284: 1534-37.
92. Arthur HM, Ure J, Smith AJ, Renforth G, Wilson DI, Torsney E, et al. Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 2000; 217: 42-53.
93. Carvalho RSL, Driessens MHE, Mummery C. Vasculogenesis and angiogenesis: lessons from genetics in mice. Comm. Theoret. Biol 2002; 7: 381-416.
94. Bourdeau A, Faughnan ME, McDonalds ML, Paterson AD, Wanless IR, Letarte M. Potential role of modifier genes influencing transforming growth factor-beta1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am J Pathol 2001; 158: 2011-20.
95. Bourdeau A, Faughnan ME, Letarte M. Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med 2000; 10: 279-85.
96. Lux A, Gallione CJ, Marchuk DA. Expression analysis of endoglin missense and truncation mutations: insights into protein structure and disease mechanisms. Hum Mol Genet 2000; 9: 745-55.
97. Roman BL, Pharm, VN, Lawson ND, Kulik M, Childs S, Lekven AC, et al. Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels. Development 2002; 129: 3009-19.
98. Polverini PJ. Angiogenesis in health and disease: insights into basic mechanisms and therapeutic opportunities. J Dent Educ 2002; 66: 962-75.
99. Fromigue O, Modrowski D, Marie PJ. Growth factors and bone formation in osteoporosis: roles for fibroblast growth factor and transforming growth factor beta. Curr Pharm Des 2004; 10(21): 2593-603.
100. Greene RM, Pisano MM. Perspectives on growth factors and orofacial development. Curr Pharm Des 2004; 10(22): 2701-17.
101. Nader HB, Lopes CC, Rocha HA, Santos EA, Dietrich CP. Heparins and heparinoids: occurrence, structure and mechanism of anti-thrombotic and hemorrhagic activities. Curr Pharm. Des 2004; 10(9): 951-66.